Innate Pharma S.A. ADS (IPHA) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Innate Pharma S.A. ADS (NASDAQ: IPHA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $1.46 (-2.67% 1D, market cap $167.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IPHA ranks #271 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPHA carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ABOS (Acumen Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $165.6M) and IVVD (Invivyd Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $177.4M). Among the 5-stock peer group, IPHA leads on earnings multiple (N/A) while TARA leads on capital efficiency (-34.7% ROIC).
For Innate Pharma S.A. ADS (IPHA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #271 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0.1% FCF Margin ($4.7M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
While IPHA currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.77) and Max Pain ($1.53) forces dealer call-delta covering toward $2.85.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Innate Pharma S.A. ADS (IPHA) dropped -2.67% to $1.46, trading at 19% of its 52-week range ($1.17 – $2.71). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
https://www.siam.in/ report covering Innate Pharma S.A. ADS (IPHA) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Innate Pharma S.A. ADS (IPHA) market action, institutional positioning, and fundamental catalysts.
MARSEILLE, France, October 27, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Ph
MARSEILLE, France, October 21, 2026--Innate Pharma to participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
MARSEILLE, France, October 20, 2026--Innate Pharma announces conference call for third quarter 2026 business and financial update
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IPHA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IPHA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Innate Pharma S.A. ADS (IPHA) ranks #271 by composite RQD confidence (52/100, grade D+) and #598 by equity capitalization ($167.6M). Within this direct 5-issuer industry benchmark cohort, IPHA leads on earnings valuation at N/A trailing P/E, while TARA leads on capital efficiency and profitability with -34.7% ROIC and — gross margin. IPHA currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IPHA
ACTIVE
Innate Pharma S.A. ADS | D+ | 52/100 | — | — | — | -2.67% | $167.6M | Benchmark Subject |
| ABOS Acumen Pharmaceuticals Inc. | D- | 38/100 | — | — | -35.0% | -90.82% | $165.6M | /abos-vs-ipha → |
| IVVD Invivyd Inc. | E | 30/100 | — | — | -35.0% | -3.37% | $177.4M | /ivvd-vs-ipha → |
| STRO Sutro Biopharma Inc. | D- | 36/100 | — | — | -35.0% | -0.44% | $151.6M | /stro-vs-ipha → |
| TARA Protara Therapeutics Inc. | D- | 43/100 | — | — | -34.7% | -1.59% | $148.9M | /tara-vs-ipha → |
Innate Pharma S.A. ADS (IPHA) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $167.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, Innate Pharma S.A. ADS (NASDAQ: IPHA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $1.46 (-2.67% 1D, market cap $167.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, IPHA ranks #271 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IPHA carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ABOS (Acumen Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $165.6M) and IVVD (Invivyd Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $177.4M). Among the 5-stock peer group, IPHA leads on earnings multiple (N/A) while TARA leads on capital efficiency (-34.7% ROIC).
For Innate Pharma S.A. ADS (IPHA), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #271 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
IPHA last traded at $1.46 (-2.67% on volume of 14,784 shares), positioning the stock -17.51% below its 50-day simple moving average ($1.77) and -14.62% below its 200-day simple moving average ($1.71). Across its 52-week range of $1.17 to $2.71, IPHA sits at the 18.8% percentile with a 14-day RSI of 40.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($1.28 to $1.64).
Why IPHA Stock dropped -2.67% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, IPHA scores 52 out of 100, a letter grade of D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are scored as follows. Fundamental Cash Engine: 12 of 20, with ROIC at 0% and FCF yield at 0%. Whale 13F Flow: 8 of 20, reflecting institutional accumulation and options positioning. Insider Conviction: 9 of 20, reflecting SEC Form 4 and Congressional PTR cluster flow. Macro Regime Fit: 10 of 20, with beta at 1.0 and sector sensitivity. Forensic Balance Sheet: 13 of 20, with Altman Z at 2.5, Piotroski F at 6 of 9, and Debt/Equity at 0.5.
For a prospective investor, the weakest pillars are the cash engine and insider/institutional flow, each of which signals limited current evidence of earnings-driven demand. The balance sheet pillar is the strongest relative to the others, which means the case rests more on balance-sheet durability than on current profitability. Because the cash-return metrics are reported at 0%, any upside thesis depends on future improvement not visible in this data. The beta of 1.0 indicates market-level sensitivity, so the rating's macro-fit score reflects no sector-specific tailwind visible in the source data. This is an analytical summary, not personalized financial advice.
Per the recent news and catalysts section, two items are listed for IPHA. The first, a market-wire item dated one hour before the data timestamp, flags a price edge-lower to $1.51 with the ADS holding near the middle of its range, marked YELLOW as a market-wire signal. The second, a catalyst item dated three hours before the data timestamp, reports on the Q2 2026 earnings with a wider-than-expected loss that overshadowed a modest stock gain, along with an upward estimate revision, marked GREEN. The earnings item is the more consequential signal, though the source does not provide the loss figures or the revision magnitude. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are recorded.
Real-time company headlines, analyst actions, and sector developments for Innate Pharma S.A. ADS (IPHA) • Click "Debate This Headline" to argue it in the Roar Pit below
https://www.siam.in/ report covering Innate Pharma S.A. ADS (IPHA) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Innate Pharma S.A. ADS (IPHA) market action, institutional positioning, and fundamental catalysts.
MARSEILLE, France, October 27, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Ph
MARSEILLE, France, October 21, 2026--Innate Pharma to participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
MARSEILLE, France, October 20, 2026--Innate Pharma announces conference call for third quarter 2026 business and financial update
Welcome to the IPHA (Innate Pharma S.A. ADS) Roar Pit. Current RQD Composite is 52/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on IPHA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Innate Pharma S.A. ADS expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on IPHA, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.46 (52-wk range $1.17 - $2.71), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).